Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Head & Neck 1

Conditions

Mucositis 1Head and Neck Neoplasms 1Abnormalities, Radiation-Induced 1

Interventions

Radiotherapy 6Cisplatin 6Radiation 3Injections 3Fibroblast Growth Factor 7 3RRx-001 2Propolis 2Methods 2Honey 2Amifostine 2pegfilgrastim 1oxycodone-acetaminophen 1kang-lai-te 1golotimod 1cyclohexaneacetic acid 1brilacidin 1acetaminophen, hydrocodone drug combination 1Xylitol 1Water 1Traumeel S 1Thioctic Acid 1Therapeutics 1Surgical Procedures, Operative 1Sucralfate 1Standard of Care 1Sodium Chloride 1Radiotherapy, Intensity-Modulated 1Psychology, Positive 1Pain Management 1Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × cyclohexaneacetic acid × Other × Clear all
NCT02480114 2021-02-18

Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation Therapy

Vanderbilt-Ingram Cancer Center

Phase 3 Completed
79 enrolled 8 charts
Head & NeckOther

Abnormalities, Radiation-Induced, Head and Neck Neoplasms, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡